Categories: News

INCERGO S.A. ADVANCES MERGER WITH VISUAL SEMICONDUCTOR BY ISSUING SHARES AND SHOWCASES GLASSES-FREE 3D DISPLAYS AT THE CONSUMER ELECTRONICS SHOW IN LAS VEGAS

LUXEMBOURG and FREMONT, Calif., Jan. 2, 2026 /PRNewswire/ — INCERGO S.A. (ICG) today announced continued progress in its merger with Visual Semiconductor Inc. (VSI), including the issuance of shares in support of the transaction and the ongoing expansion of Visual Semiconductor’s GF3D™ platform. From black–and–white to color. From flat 2D to GF3D™. The next visual revolution is here.

- Advertisement -

INCERGO and Visual Semiconductor will present live demonstrations at the Consumer Electronics Show (CES) 2026, January 6–9, at LVCC, Central Hall, Booth 21123, where the companies will showcase GF3D™ Glasses–Free 3D displays to media, partners, and investors through scheduled and private demonstrations.

- Advertisement -

The CES showcase highlights Visual Semiconductor’s GF3D™ technology, which enables immersive Glasses–Free 3D experiences without glasses, goggles, or privacy–invading eye–tracking technologies. GF3D™ operates at the display level, converting standard 2D content into immersive 3D in real time.

- Advertisement -

The GF3D™ 65–inch 8K home display is designed for large–screen viewing environments and supports Glasses–Free 3D presentation for movies, sports, concerts, streaming content, and games at typical living–room viewing distances.

- Advertisement -

The GF3D™ 6.58–inch smartphone display applies the same GF3D™ technology to mobile devices, enabling Glasses–Free 3D presentation for streaming video, games, social content, maps, user interfaces, photos, and camera previews, without the use of wearable devices.

- Advertisement -

Together, these demonstrations illustrate the scalability of GF3D™ technology across different screen sizes and use cases, extending Glasses–Free 3D beyond head–mounted AR and VR systems to everyday consumer displays.

- Advertisement -

The company believes the era of flat 2D displays has ended, and that GF3D™ represents a transition as significant as the industry’s shift from black–and–white to color.

- Advertisement -

Media and Demo Inquiries
press@visualsemi.com
bd@visualsemi.com
investors@visualsemi.com

- Advertisement -

Follow Visual Semiconductor
Snapchat: https://www.snapchat.com/add/visualsemi
TikTok: https://www.tiktok.com/@visualsemi
Instagram: https://www.instagram.com/visualsemiconductor/
Facebook: https://www.facebook.com/visualsemiconductor
LinkedIn: https://www.linkedin.com/company/visualsemi 

- Advertisement -

X: https://x.com/visualsemi

- Advertisement -

Follow INCERGO S.A.

- Advertisement -

X: https://x.com/IncergoPlc
LinkedIn: https://www.linkedin.com/company/incergo/

- Advertisement -

Recent Posts

FemiCore (Official Website & Authenticity Notice 2026) Counterfeit Risks and What Consumers Should Know

New York City, NY, June 13, 2026 (GLOBE NEWSWIRE) -- The women's health supplement market…

17 hours ago

Hitch Open Ping-Pong Embodied (HOPE) AI Challenge Joins the 2026 World Humanoid Robot Games, Seeding Advanced Physical AI Against Human Performance

BEIJING, June 13, 2026 (GLOBE NEWSWIRE) -- The 2026 Hitch Open Ping-Pong Embodied AI Challenge…

17 hours ago

Crypto News Today: AlphaPepe Unveils AlphaSwap Early Access as Bitcoin Price Prediction Eyes $250,000

MONACO, June 12, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe after…

17 hours ago

Hexaware Expands Presence in Gujarat with New Delivery Center at GIFT City

MUMBAI, India, LONDON and ISELIN, N.J., June 13, 2026 /PRNewswire/ -- Hexaware Technologies [NSE: HEXT], a…

19 hours ago

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI…

20 hours ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

June 13, 2026 07:30 ET  | Source: Intellia Therapeutics, Inc. Data from HAELO Phase 3…

20 hours ago